Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Hyperglycaemia? 336 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 336 reports of Hyperglycaemia have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.9% of all adverse event reports for EMPAGLIFLOZIN.

336
Reports of Hyperglycaemia with EMPAGLIFLOZIN
0.9%
of all EMPAGLIFLOZIN reports
30
Deaths
224
Hospitalizations

How Dangerous Is Hyperglycaemia From EMPAGLIFLOZIN?

Of the 336 reports, 30 (8.9%) resulted in death, 224 (66.7%) required hospitalization, and 50 (14.9%) were considered life-threatening.

Is Hyperglycaemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMPAGLIFLOZIN. However, 336 reports have been filed with the FAERS database.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Hyperglycaemia?

INSULIN GLARGINE (1,903) METFORMIN (1,626) ALPELISIB (1,575) DEXAMETHASONE (1,169) PREDNISONE (1,135) INSULIN LISPRO (743) PREDNISOLONE (705) INSULIN ASPART (646) INSULIN HUMAN (620) METHYLPREDNISOLONE (604)

Which EMPAGLIFLOZIN Alternatives Have Lower Hyperglycaemia Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Hyperglycaemia Reports All Drugs Causing Hyperglycaemia EMPAGLIFLOZIN Demographics